Clinical trials: Psilocybin
Posttraumatic Stress Disorder (PTSD)
Psilocybin-Assisted Psychotherapy for Veterans With PTSD
This study will evaluate the feasibility, safety and preliminary efficacy of psilocybin-assisted psychotherapy in military veterans with treatment-refractory posttraumatic stress disorder (PTSD).
- Trial name
- PsiVet (NCT07792538)
- Testing
- Psilocybin-assisted Psychotherapy
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- ARQ National Psychotrauma Centre
Psychedelic Experiences
Safety for Home Administration of Microdose Psilocybin Use
The goal of this laboratory study is to establish whether and which microdoses of psilocybin are safe to administer at home to healthy participants.
- Trial name
- NCT06450210
- Testing
- psilocybin trihydrate
- Where
- United States
- Volunteers
- 17 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Depression, Parkinson's Disease (PD)
The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease
The purpose of this study is to understand whether people with Parkinson's Disease and depression have improvement in their symptoms after psilocybin therapy.
- Trial name
- PSI-PD (NCT07610369)
- Testing
- Psilocybin (drug)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Yale University
Healthy
UW Psilocybin Pharmacokinetics Study
Psilocybin is a naturally occurring psychedelic compound produced by more than 200 species of mushrooms, collectively known as psilocybin mushrooms.
- Trial name
- NCT02163707
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Healthy
Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness
Psilocybin (active compound of "magic mushrooms") is a prototypical psychedelic substance that acts via agonism on serotonin (5-HT) 2A receptors. Psilocybin is rapidly metabolized into its active metabolite psilocin.
- Trial name
- PDR (NCT06796361)
- Testing
- Ketanserin 40mg plus Psilocybin 40mg, 40mg Psilocybin, 20mg Psilocybin
- Where
- Switzerland
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland
Psychological Distress
Psilocybin Microdose for Psychological and Existential Distress in Palliative Care (PSYCHED-PAL-RCT)
About 30-50% of patients with advanced illness experience depression, anxiety, or decreased sense of purpose and autonomy. Together, these are called psychological distress.
- Trial name
- NCT07063862
- Testing
- Psilocybin
- Where
- 7 sites in Canada
- Volunteers
- 120 people
- Sponsor
- Bruyère Health Research Institute.
Healthy
Effects of Hallucinogens and Other Drugs on Mood and Performance
This non-treatment study will investigate the effects on mood and performance caused by hallucinogens and other psychoactive compounds.
- Trial name
- NCT02033707
- Testing
- Hallucinogens and psychoactive substances
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Chronic Low-back Pain
Psilocybin Therapy for Chronic Low Back Pain
This study evaluates whether psilocybin therapy helps patients cope with chronic low back pain more effectively. Patients may be recruited at Stanford and University of California San Francisco (UCSF), study procedures will occur…
- Trial name
- POP (NCT05351541)
- Testing
- Psilocybin therapy with Zolpidem and Modafinil, Psilocybin therapy with Zolpidem, Psilocybin therapy with Modafinil
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Joshua Woolley, MD, PhD
Phantom Limb Pain
Psilocybin-assisted Therapy for Phantom Limb Pain
This double-blind placebo-controlled pilot study seeks to investigate whether psilocybin can be safely administered to people with chronic phantom limb pain (PLP) in a supportive setting with close follow-up, and its effects on…
- Trial name
- NCT05224336
- Testing
- Psilocybin
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Diego